

ASX/Media Release

3 February 2017

Botanix Announces Expansion of Permetrex™ License

- Expansion of license enables use of Permetrex skin delivery technology for all drugs for skin diseases, not just cannabinoids
- Recent clinical trial supports safety and low irritancy performance of Permetrex
- The expanded scope of license offers potential to develop complementary skin products that can be rapidly marketed and partnered

Perth Australia, 3 February 2017: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or “The Company”) today announced that it has executed a substantial expansion of its license to the novel Permetrex skin delivery technology.

Permetrex is utilised as the delivery formulation for the Company’s lead product for the treatment of acne, BTX-1503, which is progressing rapidly through clinical development. The first human study involving Permetrex was completed in December 2016 and showed that the delivery technology was safe and had minimal irritancy potential.

Before the execution of the license expansion, Botanix’s license was limited to using Permetrex only with cannabinoids, including the synthetic cannabidiol that forms the active in BTX-1503. The license has now been expanded to allow the use of Permetrex skin delivery technology with any drug actives that can be used to treat skin diseases.

“We are very pleased to have completed this extension of our Permetrex license”, Botanix Executive Director Matt Callahan commented, “having access to the technology for a range of other drugs provides new opportunities for the Company to expand its pipeline of novel skin disease treatments.”

Permetrex provides a more effective way of delivering drugs into the skin that is non-irritating, does not use chemicals that dry out the skin, and does not require the use of preservatives that can cause serious allergic reactions. As many existing dermatology products use sub-optimal formulations that suffer from these limitations, a range of marketed skin disease drugs can be substantially improved utilising the Permetrex approach.

“Because the underlying drug active is already approved and marketed, new and improved Permetrex enabled products can be developed quickly and commercialised without the need to submit the new products for FDA or other regulatory agency approval”, Mr Callahan said, “we plan to augment our pipeline with a number of these opportunities which are complementary to our lead acne program.”

About Botanix Pharmaceuticals

Botanix Pharmaceuticals is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which has a well-established safety profile. Botanix is preparing for the first human trials with synthetic cannabidiol utilising a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

For more information on Botanix, please visit www.botanixpharma.com or follow us on Twitter @Botanixpharma.

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals Ltd
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com

Investor Relations

Ben Walsh
WE Buchan
P: 02 9237 2801
E: bwalshrwilson@buchanwe.com.au

Media enquiries

Arthur Chan
WE Buchan
P: (02) 9237 2805
E: achan@buchanwe.com.au